04:45 PM EDT, 04/08/2025 (MT Newswires) -- Serina Therapeutics ( SER ) said Tuesday that it raised $5 million in financing from shareholders, which will be utilized to support the development of POZ-apomorphine to treat Advanced Parkinson's disease.

The phase 1 clinical trial of the candidate is expected to commence in Q4, the company said.

The company raised the financing by issuing 965,250 shares of convertible preferred stock at $5.18 per share.